中國人壽(601628.SH)大漲超5% 創逾4年新高
格隆匯11月4日丨中國人壽(601628.SH)今日大漲,現報35.1元,漲5.34%,盤中最高價35.2元創2015年7月以來新高,暫成交6.76億元,最新總市值9921億元。
H股漲0.97%報20.75港元。

其他A股保險股中,中國太保漲超2%,新華保險、西水股份、天茂集團、中國人保和中國平安漲幅均在1%以內。
10月29日中國人壽公佈的財報顯示,前三季度歸屬於母公司股東的淨利潤577.02億元,同比增190.4%。
對於中國人壽利潤大增的原因,有分析師認為,主要是投資管理體系深化改革成效顯著,固收類投資及權益類投資收益均大幅增長。
招商證券指出,站在當前時點,將保險股列為後續兩個季度的首選子行業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.